What Is Tesamorelin? Benefits, Research & Safety

Tesamorelin was developed by Theratechnologies, a Canadian biopharmaceutical company, in the early 2000s. The peptide was designed as a stabilised analogue of naturally occurring GHRH with improved pharmacokinetic properties. The development focus was on HIV-associated lipodystrophy, a syndrome characterised by abnormal fat distribution—particularly visceral fat accumulation—seen in many HIV-positive patients, often associated with antiretroviral therapy. Clinical development included multiple Phase III trials demonstrating significant reductions in trunk fat with tesamorelin treatment compared to placebo. Studies showed meaningful reductions in visceral adipose tissue measured by CT scan. In November 2010, the FDA approved tesamorelin (Egrifta) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. This approval made it the first medication specifically approved for this indication. The EMA did not approve tesamorelin, citing concerns about the clinical benefit-risk balance for the EU population. Research continues into potential applications in other conditions including cognitive decline in older adults and broader metabolic indications.